Last updated: February 26, 2026
What does the patent RU2420279 cover?
Patent RU2420279, titled "Composition for treating or preventing diseases associated with oxidative stress," was granted in Russia in 2011. It claims a pharmaceutical composition comprising specific active ingredients aimed at mitigating oxidative damage.
Summary of core claims:
- A pharmaceutical composition with a combination of compounds: a flavonoid (e.g., quercetin) and a non-steroidal anti-inflammatory agent (e.g., indomethacin).
- Method of use for treatment or prevention of conditions related to oxidative stress, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions.
- A specific dosage regimen and form (e.g., tablets, capsules).
What are the primary claim features?
The patent encompasses claims divided into two categories:
Composition Claims
- Claims emphasizing the combination of flavonoid and anti-inflammatory agent.
- Defines dosage ranges (e.g., flavonoid: 10-100 mg; anti-inflammatory: 25-50 mg).
- Claims include various forms, such as controlled-release formulations.
Method Claims
- Use of the composition for reducing oxidative stress.
- Specific indications: ischemic vascular disease, Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
- Administration protocols, including frequency and duration.
Limitations
- The claims are dependent on specific active ingredients and dosages.
- The scope excludes unrelated compounds or alternative formulations not explicitly mentioned.
Patent landscape around RU2420279
Patent family and regional filings
- The patent family includes applications in Eurasia, China, and the European Patent Office (EPO).
- EPC counterparts were filed around 2012, with some having been granted.
- Partnered with regional patent offices, expanding protection and licensing scope.
Similar patents and prior art
- Closest prior art consists of patents and publications describing antioxidant compositions with flavonoid and NSAID combinations.
- Notably, WO2009027345 (published in 2009) describes similar combinations for oxidative stress.
- The Russian patent differentiates itself by specific dosages and particular methods of use.
Patent expiration and statuses
- Filed in 2010, with a standard 20-year protection duration; expiration is expected around 2030 unless maintenance fees are unpaid.
- Some patents in the family remain active; others face potential lapses due to non-payment or legal challenges.
Patent strength considerations
- Claims are narrowly focused on specific combinations and dosages.
- Known prior art indicates these may be vulnerable to valid invalidity arguments.
- The patent's enforceability is contingent on regional patentability criteria, with potential objectivity challenges owing to established prior art.
Competitive landscape
- The concept of antioxidant and anti-inflammatory combinations is well-explored.
- Multiple companies have filed similar applications targeting cardiovascular and neurodegenerative diseases.
- No evidence of broad, blocking patents covering this specific combination in Russia or Eurasia.
Strategic implications for stakeholders
- The patent provides limited scope but can serve for licensing or regional exclusivity.
- Overlap with prior art suggests vigilance for potential patent invalidation.
- The niche focus aligns with certain therapeutic indications but faces competition from generic and supplementary innovations.
Key Takeaways
- RU2420279 covers a combination of a flavonoid and NSAID formulations for oxidative stress-related diseases.
- Claims are specific to compositions, dosages, and certain indications.
- The patent landscape includes similar filings and prior art, narrowing the scope of enforceability.
- The patent is likely to expire in 2030, with ongoing patent prosecution and opposition leading to potential challenges.
- Competition exists, with multiple patent filings regarding antioxidant formulations in Russia and Eurasia.
FAQs
1. What is the core innovation of RU2420279?
It claims a specific composition combining a flavonoid (e.g., quercetin) with an NSAID (e.g., indomethacin) for therapeutic applications related to oxidative stress.
2. How broad are the claims?
The claims are narrowly focused on particular combinations, dosages, and treatment methods, limiting scope to specific formulations and uses.
3. How does this patent compare to similar international filings?
The patent's claims are similar to prior art publications like WO2009027345, with differences in specific ratios and indications. It does not represent a broad, foundational patent in the space.
4. Are there risks of patent invalidation?
Yes. The prior art suggests potential invalidity unless the patent's specific claims can be distinguished legally.
5. Who are the main competitors in this space?
Other companies developing antioxidant and neuroprotective formulations in Russia and Eurasia. Existing patent filings cover parts of similar compounds and uses.
References
- Patent RU2420279, "Composition for treating or preventing diseases associated with oxidative stress," Russian Patent Office, 2011.
- World Intellectual Property Organization. (2009). WO2009027345 - Antioxidant composition. [Online] Available at: https://patents.google.com/patent/WO2009027345A1
- European Patent Office. (2012). EP2516764 - Composition patent family filings. [Online] Available at: https://espacenet.com
